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INTRODUCTION
Bone marrow transplantation (BMT) and peripheral
blood stem cell transplantation after high-dose chemo-
therapy have become standard therapies for many hemato-
logic disorders and malignancies. However, the significant
morbidity and mortality associated with transplantation
therapy, especially allogeneic transplantation, continue to be
a major concern for physicians and patients. Pulmonary
complications account for a signiﬁcant percentage of deaths
during the ﬁrst 100 days after transplantation [1,2].
Pulmonary complications after BMT may be due to
infectious or noninfectious conditions and are classified as
early or late depending on whether they occur before or after
day 100 posttransplantation. Common early complications
include pulmonary edema, infectious pneumonia, and idio-
pathic pneumonitis. Diffuse alveolar hemorrhage (DAH), a
type of idiopathic pneumonia, is characterized by multilobar
culture-negative lung injury with alveolar hemorrhage indi-
cated by increasing bloody return on successive aliquots of
bronchoalveolar washings [3]. Despite the use of high-dose
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ABSTRACT
Pulmonary complications are a significant cause of early mortality (before day 100) after bone marrow transplanta-
tion (BMT). To identify factors associated with development of early post-BMT severe pulmonary complications
(SPCs), we conducted a retrospective review of the medical records of 339 consecutive patients who underwent
hematopoietic stem cell transplantation for hematologic disorders and identified pulmonary complications that
occurred before day 60 posttransplantation. SPCs, defined as (1) diagnosis of diffuse alveolar hemorrhage, (2) need
for mechanical ventilation, or (3) death from respiratory failure, occurred in 48 (24%) of 199 patients receiving allo-
geneic transplants and 4 (2.9%) of 140 patients receiving autologous transplants (P < .001). Multiple clinical vari-
ables were analyzed to determine their influence on the development of SPCs in allogeneic marrow recipients. The
method of graft-versus-host disease (GVHD) prophylaxis was the single most important factor affecting SPC inci-
dence. Of patients who received cyclosporine/methotrexate (CYA/MTX) as GVHD prophylaxis, 33% experienced
SPCs compared with 8% of those receiving T-cell depletion (TCD) alone (P < .0001). Multivariate analysis con-
firmed that TCD was associated with a lower risk of SPCs (relative risk [RR], 0.18; P = .0006). In addition to GVHD
prophylaxis, a reduced pretransplantation FEV1 (forced expiratory volume in 1 second) (≤80% of predicted) was
associated with an increased risk for SPCs (odds ratio, 4.4; P = .0025). Grades 2 to 4 acute GVHD, tobacco use, age
≥50 years, sex, unrelated donor, cytomegalovirus serologic status, disease status at transplantation, pretransplanta-
tion carbon monoxide diffusing capacity, and total body irradiation were not associated with development of SPCs.
We conclude that autologous BMT is associated with a significantly lower incidence of SPCs compared with allo-
geneic BMT and that for allogeneic BMT, GVHD prophylaxis using TCD is associated with a significantly lower
risk for SPCs compared with prophylaxis using CYA/MTX. Patients with pretransplantation FEV1 of ≤80% appear
to have a higher risk for SPCs.
KEY WORDS 
Pulmonary toxicity • Bone marrow transplantation • Diffuse alveolar hemorrhage •
T-cell depletion • Pulmonary function tests
Biology of Blood and Marrow Transplantation 7:223-229 (2001)
© 2001 American Society for Blood and Marrow Transplantation ASBMT
V.T. Ho et al.
224
corticosteroids, mortality from DAH and other idiopathic
pneumonias has been reported to be greater than 80% [3-6].
Because post-BMT pulmonary complications are associ-
ated with high rates of morbidity and mortality, identiﬁca-
tion of predisposing factors is crucial for the development of
preventive strategies. In this study, we identiﬁed all cases of
severe pulmonary complications (SPCs) occurring within
60 days of stem cell infusion in a consecutive series of autol-
ogous, syngeneic, and allogeneic transplant recipients at our
institution from February 1997 to June 1998. Univariate
and multivariate analyses were performed to identify pre-
transplantation factors that independently predicted the
development of SPCs.
MATERIALS AND METHODS
Identification of Pulmonary Complications
Data were retrieved retrospectively from all patients
who underwent autologous or allogeneic stem cell trans-
plantation (n = 339) for hematologic disorders from Febru-
ary 1, 1997, to June 30, 1998. Records were reviewed for
evidence of development of pulmonary complications from
day 0 to 60 after the infusion of stem cells. Available pre-
transplantation data included age, sex, disease status at
transplantation, cytomegalovirus (CMV) status, smoking
history, pretransplantation pulmonary function test results,
history of pulmonary disease, prior chest irradiation, and
prior intubation. Pretransplantation pulmonary function
tests were performed within 4 to 6 weeks of the date of
transplantation.
Potential pulmonary complications were identified by
reviewing radiology reports for all chest x-rays performed
from day 0 to day 60 after the marrow or stem cell infusion.
New abnormal chest x-ray ﬁndings were ﬂagged for medical
record review to conﬁrm pulmonary complications. When
chest x-ray reports were equivocal, follow-up chest x-rays,
if available, were used for clariﬁcation. In addition to chest
x-ray reports, discharge summaries for all patients were
reviewed to ensure that no pulmonary complications were
overlooked (such as pulmonary embolism that may have
occurred with a normal chest x-ray).
When a potential pulmonary complication was identi-
ﬁed by an abnormal chest x-ray, a follow-up medical record
review was performed. Information was collected regarding
presence of acute graft-versus-host disease (GVHD), diag-
nostic procedures, microbiologic data, radiology studies,
autopsy results, and the final impressions about the pul-
monary process. The latter were based on review of consult
notes made at the end of the clinical course by the attending
or pulmonary physician. When autopsies or biopsies of the
lung were available, pathology reports were correlated with
these ﬁnal clinical impressions.
Definitions of SPCs
SPC was deﬁned as any of the following: (1) diagnosis of
DAH, (2) requirement for mechanical ventilation, and (3)
death due to respiratory failure in patients without DAH
who chose not to receive mechanical ventilation.
Diagnosis of DAH required observation of multilobar
infiltrates on chest x-ray, absence of an identifiable
pathogen, and demonstration of increasing blood return on
repeated aliquots of bronchoalveolar washing. Cases in
which DAH was suspected but bronchoscopy was nondiag-
nostic or not performed were classified as DAH only if a
DAH diagnosis was documented in the medical record and
treatment for DAH was administered. Patients with infec-
tious or noninfectious causes of pulmonary dysfunction
severe enough to result in intubation or death (such as dif-
fuse alveolar damage and adult respiratory distress syn-
drome) were included in this analysis.
Patients
For the purpose of analysis, patients were stratiﬁed into
early, intermediate, and advanced disease groups based on
their disease status prior to undergoing transplantation. The
early disease group included patients with aplastic anemia,
acute leukemia, or lymphoma in first complete remission;
patients with chronic myelogenous leukemia (CML) in sta-
ble phase; and patients with myelodysplastic syndrome cate-
gorized as refractory anemia or refractory anemia with
ringed sideroblasts. The intermediate disease group
included patients with acute myelogenous leukemia (AML)
or acute lymphocytic leukemia (ALL) in second or subse-
quent complete remission; patients with CML in accelerated
phase; patients with chronic lymphocytic leukemia (CLL),
non-Hodgkin’s lymphoma (NHL), or Hodgkin’s disease in
partial remission; patients with myelodysplastic syndrome
categorized as refractory anemia with excess blasts or refrac-
tory anemia with excess blasts in transformation; and
patients with chronic monomyelocytic leukemia. In addi-
tion, all patients with multiple myeloma and amyloidosis
were placed in the intermediate disease group. The
advanced disease group included patients with CML in blast
crisis and patients with AML, ALL, NHL, and Hodgkin’s
disease in relapse or induction failure. Patients with sec-
ondary AML were considered to be in the advanced disease
group regardless of remission status.
Transplantation Protocols
Conditioning regimens used in the study population
included cyclophosphamide/total body irradiation (Cy/TBI),
cyclophosphamide/carmustine/etoposide (CBV), busulfan/
cyclophosphamide (Bu/Cy), Cy alone, and melphalan/TBI.
All allogeneic transplant recipients received bone marrow as
the source of stem cells. In the autologous transplantation
group, peripheral blood stem cells were used in those
patients conditioned with CBV; all other patients in this
group received autologous bone marrow.
Patients undergoing allogeneic transplantation were
divided into 2 groups based on the GVHD prophylaxis they
received: T-cell depletion (TCD) or cyclosporine/metho-
trexate (CYA/MTX). The TCD group received allografts
that were treated ex vivo with anti-CD6 monoclonal anti-
body plus rabbit complement [7]. Posttransplantation
immunosuppressive medications were not given prophylacti-
cally. In the CYA/MTX group, GVHD prophylaxis included
the administration of CYA from day –3 and MTX on days 1,
3, 6, and 11, with or without methylprednisolone [8,9].
The decision to use TCD versus CYA/MTX was made
prior to transplantation by the BMT physician after consid-
ering the patient’s underlying malignancy and coexisting
medical conditions that could adversely affect the outcome
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of transplantation. Patients with CML were more likely to
receive CYA/MTX because the graft-versus-leukemia effect
appears to be important in this disease, and evidence sug-
gests a higher rate of relapse after TCD transplantation
[10]. On the other hand, for patients with signiﬁcant comor-
bid conditions, TCD transplantation may be a favorable
option because it is associated with lower risk of GVHD and
lower incidence of early transplantation-related mortality
[7]. In our study population, the bias to treat stable-phase
CML with T-replete BMT accounted for the higher per-
centage of early disease patients in the CYA/MTX group.
Unless contraindicated because of allergic reactions,
antibiotic prophylaxis consisted of sulfamethoxazole/
trimethoprim for all patients until day 0, followed by a
quinolone antibiotic in the TCD and autologous trans-
plantation groups. TCD and autologous transplantation
patients also received filgrastim until the absolute neu-
trophil count (ANC) was above 1000. Day of engraftment
was defined as the day when the ANC reached 500. Pneu-
mocystis carinii pneumonia prophylaxis was started at
approximately day 30. Acyclovir was given as prophylaxis
for most patients upon admission. Patients with positive
donor/recipient CMV serologies received CMV prophy-
laxis with intravenous ganciclovir at day 30, unless con-
traindicated by poor neutrophil recovery.
Statistical Analysis
Univariate analysis of transplantation variables for the
development of SPCs was performed using a log-rank test
[11]. The predictive value of the covariates for SPCs was
assessed by multivariate analysis using a Cox proportional
hazards regression model for the time to SPCs [12]. The
Kaplan-Meier method was used to estimate the time to SPC
[13]. Data from patients who did not experience an SPC
within 60 days were censored at 60 days. Data from
5 patients who died of nonpulmonary causes within 60 days
were censored at the time of death.
RESULTS
Patient Characteristics
From February 1997 to June 1998, 339 patients under-
went BMT or peripheral blood stem cell transplantation at
our institution. There were 137 autologous, 199 allogeneic,
and 3 syngeneic transplants. Because they were conditioned
similarly and did not receive GVHD prophylaxis, the
3 patients who underwent syngeneic transplantation were
grouped with the patients who underwent autologous trans-
plantation. Patient characteristics are shown in Table 1. The
median patient age for the autologous/syngeneic transplan-
tation group was 50 years (range, 18-72 years). The median
age for the allogeneic transplantation patients was 44 years
(range, 19-66 years).
Characteristics of the 199 allogeneic transplant recipi-
ents are shown in Table 2. Age, sex, CMV status, smoking
history, and TBI conditioning were similar in the TCD and
CYA/MTX groups. The distribution of advanced disease
patients did not differ signiﬁcantly between these 2 groups.
There were more patients with early disease status in the
CYA/MTX group because there were more patients with
stable-phase CML in this population.
Table 1. Characteristics of 339 Hematopoietic Stem Cell Transplant Recipients*
Autologous/ Allogeneic
Syngeneic Transplant
Transplant Recipients,
Recipients, n (%) n (%)
Age, y
Median (range) 50 (18-72) 44 (19-66)
<50 65 (46.4) 139 (69.8)
≥50 75 (53.6) 60 (30.2)
Men 81 (57.9) 108 (54.3)
Women 59 (42.1) 91 (45.7)
Disease status at transplantation
Early 2 (1.4) 92 (46.2)
Intermediate 131 (93.6) 84 (42.2)
Advanced 7 (5.0) 23 (11.6)
Type of allogeneic transplantation
Related/TCD 54 (27.1)
Related/CYA/MTX 76 (38.2)
Unrelated/TCD 22 (11.1)
Unrelated/CYA/MTX 47 (23.6)
GVHD prophylaxis
TCD 76 (38.2)
CYA/MTX 123 (61.8)
Preparative regimen
Cy/TBI 62 (44.3) 182 (91.5)
BU/Cy 7 (5.0) 8 (4.0)
CBV 43 (30.7) 0 (0.0)
MEL/TBI 28 (20.0) 4 (2.0)
Cy 0 (0.0) 5 (2.5)
Donor-patient cytomegalovirus status
Negative/negative 85 (43.2)
All others 112 (56.8)
Smoking
Never 57 (40.7) 106 (53.3)
Quit for >1 y 30 (21.4) 44 (22.1)
Active 21 (15.0) 34 (17.1)
Unknown 32 (22.9) 15 (7.5)
History of pulmonary disease
No 112 (80.0) 155 (77.9)
Yes 28 (20.0) 44 (22.1)
Prior intubation
No 137 (97.9) 195 (98.0)
Yes 3 (2.1) 4 (2.0)
Prior chest irradiation
No 120 (85.7) 186 (93.5)
Yes 20 (14.3) 13 (6.5)
Pretransplantation PFT
FEV1 
≤ 80% 28 (21.2) 19 (9.9)
>80% 104 (78.8) 173 (90.1)
Missing 8 8
FEV1/FVC 
≤ 80% 5 (3.8) 8 (4.2)
>80% 127 (96.2) 183 (95.8)
Missing 8 8
DLCO 
≤ 80% 45 (34.6) 61 (37.4)
>80% 85 (65.4) 103 (62.8)
Missing 10 35
*TCD indicates T-cell depletion; CYA/MTX, cyclosporine/
methotrexate; GVHD, graft-versus-host disease; Cy/TBI, cyclophos-
phamide/total body irradiation; BU, busulfan; CBV, cyclophos-
phamide/carmustine/etoposide; MEL, melphalan; PFT, pulmonary
function test; FEV1, forced expiratory volume in 1 second; FVC,
forced vital capacity; DLCO, carbon monoxide diffusing capacity.
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Pulmonary Complications
The distribution of abnormal chest radiographs in the
2 transplantation treatment groups is shown in Table 3.
Among autologous/syngeneic transplant recipients, there
were 11 cases of infectious or presumed infectious pneumo-
nia, 1 case of DAH, and 19 cases of other noninfectious
pulmonary complications. Among allogeneic transplant
recipients, there were 39 cases of infectious or presumed
infectious pneumonia, 23 cases of DAH, and 52 cases of
other noninfectious pulmonary complications.
A total of 52 cases of SPC were identified, 48 in the
allogeneic and 4 in the autologous/syngeneic group. A
majority of SPCs developed in allogeneic transplant recipi-
ents who received CYA/MTX as GVHD prophylaxis. The
incidence of SPCs was 33% after allogeneic BMT with
CYA/MTX, 8% after allogeneic BMT with TCD, and 3%
after autologous/syngeneic BMT (P < .0001). Among the
allogeneic patients, there were 23 with DAH, 16 (70%) of
whom required mechanical ventilation. The other cases of
SPCs included 20 patients without DAH who required
mechanical ventilation and 5 non-DAH patients who died of
respiratory failure after refusing intubation. In the autolo-
gous/syngeneic group, 1 patient had DAH, 2 required
mechanical ventilation for pneumonia, and 1 died of respira-
tory failure without intubation or DAH.
Risk Factors for the Development of SPCs
Because of the small number of SPCs in the autolo-
gous/syngeneic group, we have elected to limit our analyses
of risk factors to the allogeneic transplantation population.
Fifteen risk factors were included in the univariate analysis.
As shown in Tables 4 and 5, the only factor that was statisti-
cally significant (α < 0.05) was GVHD prophylaxis. SPCs
occurred in only 8% of patients who received TCD trans-
plants compared with 33% of patients who received
CYA/MTX as GVHD prophylaxis (P < .0001). This differ-
ence is illustrated in Figure 1, which shows the time-to-SPC
curves for these 2 populations. Age greater than 50 years,
sex, marrow source (related versus unrelated), disease status,
CMV status, tobacco use, history of pulmonary disease, and
pretransplantation pulmonary function tests were not asso-
ciated with significant changes in risk for SPCs. Previous
chest irradiation and prior intubation were also not statisti-
cally significant in this analysis, although the numbers in
these categories were too small for meaningful conclusions.
Likewise, because only 13 (6.5%) of 199 allogeneic patients
did not receive TBI as part of their conditioning regimen,
there were insufﬁcient data to assess the risk of TBI versus
no TBI in this population.
In multivariate Cox proportional hazards regression analy-
sis, GVHD prophylaxis was again the most signiﬁcant risk fac-
tor for the development of SPCs. Allogeneic transplantation
patients who received TCD alone as GVHD prophylaxis had
a signiﬁcantly lower risk of developing SPCs compared with
patients who received CYA/MTX (relative risk [RR], 0.18;
conﬁdence interval [CI], 0.07-0.47). In the multivariate analy-
sis, pretransplantation FEV1 (forced expiratory volume in
1 second) of ≤80% of predicted was also a statistically signiﬁ-
cant predictor of SPCs (RR, 4.4; CI, 1.81-10.66).
Among allogeneic patients with SPCs, 89% had grades
0 to 1 GVHD on the day of the ﬁrst abnormal chest x-ray,
9% had grade 2 GVHD, and 2% had missing GVHD infor-
mation. The presence of grades 2 to 4 acute GVHD at the
onset of the pulmonary process was analyzed using a time-
varying multivariate analysis to determine whether GVHD
predisposed patients to the development of SPCs. We found
that the presence of grades 2 to 4 GVHD at the time of the
ﬁrst abnormal chest x-ray was not associated with the devel-
opment of SPCs (P = .53).
Most SPCs began prior to neutrophil engraftment.
Among the 46 patients who developed SPCs, 36 (78%) had
onset of pulmonary complications (deﬁned by ﬁrst abnormal
chest radiograph) before an ANC of 500, and only 10 (22%)
after. The median time to onset of SPC was 13 days, com-
pared with a median time of engraftment of 24 days
(Figure 2). Engraftment times among patients with and
without SPCs were similar in both the TCD and
CYA/MTX treatment populations.
DISCUSSION
SPCs, although relatively uncommon after autologous
BMT, are an important cause of morbidity and mortality
after allogeneic BMT. In this study, we analyzed risk factors
for the development of early SPCs after allogeneic BMT.
The most signiﬁcant ﬁnding was that TCD was associated
with a significantly lower incidence SPCs compared with
Table 2. Characteristics of Allogeneic Transplant Recipients*
TCD CYA/MTX
(n = 76) (n = 123) P
Age, <50 y 52 (68.4%) 87 (70.7%) .75
Men 44 (57.9%) 64 (52.0%) .47
Cytomegalovirus status .46
Negative/Negative 35 (46.1%) 50 (41.0%)
Other 40 (53.5%) 72 (59.0%)
Smoking .69
Never 40 (61.5%) 66 (55.5%)
Quit for >1 y 15 (23.1%) 29 (24.4%)
Active 10 (15.4%) 24 (20.2%)
Disease Status .005
Early 25 (32.9%) 67 (54.5%)
Intermediate 43 (56.6%) 41 (33.3%)
Advanced 8 (10.5%) 15 (12.2%)
TBI conditioning 73 (96.1%) 113 (91.9%) .38
*TCD indicates T-cell depletion; CYA/MTX, cyclosporine/
methotrexate; TBI, total body irradiation.
Table 3. Abnormal Chest Radiographs in 339 Hematopoietic Stem Cell
Transplant Recipients
Type of Transplant Received
Clinical Correlate Autologous/ Allogeneic
of Chest Radiograph Syngeneic (n = 140) (n = 199)
Infection-related lung injury* 11 39
Not infection-related lung injury 19 52
Diffuse alveolar hemorrhage 1 23
*Or presumed to be infection related.
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GVHD prophylaxis using CYA/MTX. Breuer et al. have
previously reported a relatively low incidence (7.5%) of fatal
interstitial pneumonitis after T cell–depleted BMT [14], but
our study is the ﬁrst to demonstrate a statistically signiﬁcant
difference in the incidence of SPCs in T cell–depleted BMT
compared with T cell–replete BMT.
The pathogenesis of SPCs after BMT is not well under-
stood. Given the lower incidence of GVHD after TCD
transplantation, one may speculate that the lower incidence
of SPCs observed here is related to decreased acute GVHD.
However, our analyses have not supported this theory. Using
a time-varying multivariate model, we found no statistical
association between the presence of grades 2 to 4 GVHD at
the time of the ﬁrst abnormal chest x-ray and the develop-
ment of SPCs. We have further shown that most SPCs
began prior to neutrophil engraftment (ANC = 500), before
the time one would expect to see any GVHD clinically.
Other differences between the TCD and CYA/MTX
GVHD prophylaxis groups may be important in the patho-
genesis of SPCs. Patients who receive CYA/MTX as GVHD
prophylaxis may be predisposed to SPCs because of the
immunosuppressive or direct pulmonary toxic effects associ-
ated with these medications. Alternatively, alloreactive mecha-
nisms other than classic GVHD, such as subclinical GVHD or
pulmonary GVHD, could cause injury to the lungs and pre-
dispose non-TCD patients to SPCs. This theory is supported
by murine models that have identiﬁed minor H-antigen mis-
matches and host-reactive donor T lymphocytes as important
factors in the pathogenesis of idiopathic pneumonia after
BMT; in addition, other recent data show high tissue levels of
T helper 2–associated cytokines in the lungs of patients with
idiopathic pneumonia syndrome [15-17]. It is plausible that
these T cell–mediated mechanisms are retarded in patients
who receive allografts modiﬁed by anti-CD6 TCD.
Another difference between the TCD and CYA/MTX
groups is the use of granulocyte colony-stimulating factor
(G-CSF) in the TCD transplant recipients. Because growth
factors have been shown to decrease the time to engraft-
ment after T cell–depleted allogeneic BMT [18,19], it is
conceivable that the shortened duration of neutropenia could
protect against certain infectious pulmonary complications.
Although growth factors have been shown to reduce engraft-
ment time, hospitalization time, and bacterial infections after
autologous BMT [20-24], evidence for similar beneﬁts after
allogeneic transplantation is less clear. In allogeneic BMT,
Table 4. Factors Included in the Univariate Analysis of the Development of
Severe Pulmonary Complications (SPCs) After Allogeneic Bone Marrow
Transplantation*
P 
SPC (Log-Rank 
Factor No (n = 152) Yes (n = 47)† Test)
Age, y .46
<50 108 (78%) 31 (22%)
≥50 44 (73%) 16 (27%)
Sex .52
Male 81 (75%) 27 (25%)
Female 71 (78%) 20 (22%)
Disease status at 
transplantation .17
Early 65 (71%) 27 (29%)
Intermediate 69 (82%) 15 (18%)
Advanced 18 (78%) 5 (22%)
Unknown 1 0
Source of marrow .14
Related donor 104 (80%) 26 (20%)
Unrelated donor 48 (70%) 21 (30%)
Donor/patient 
cytomegalovirus status .57
Negative/negative 66 (78%) 19 (22%)
All others 84 (75%) 28 (25%)
Unknown 2 0
Smoking history .30
Never 84 (79%) 22 (21%)
Quit for >1 y 31 (70%) 13 (30%)
Active 24 (71%) 10 (29%)
Unknown 13 2
GVHD prophylaxis <.0001
CD6+ TCD alone 70 (92%) 6 (8%)
CYA/MTX 82 (67%) 41 (33%)
Preparative regimen .44
TBI 9 (69%) 4 (31%)
No TBI 143 (77%) 43 (23%)
History of pulmonary 
disease .29
No 121 (78%) 34 (22%)
Yes 31 (70%) 13 (30%)
History of chest irradiation .99
No 142 (76%) 44 (24%)
Yes 10 (77%) 3 (23%)
History of prior intubation .89
No 149 (76%) 46 (24%)
Yes 3 (75%) 1 (25%)
*GVHD indicates graft-versus-host disease; CYA/MTX, cyclo-
sporine/methotrexate; TCD, T-cell depletion; TBI, total body
irradiation.
†Note that 48 SPCs were observed in 47 patients.
Table 5. Univariate Analysis of Pretransplantation Pulmonary Function
Tests for the Development of Severe Pulmonary Complications (SPCs) in
Allogeneic Patients* 
Pulmonary SPC P
Function Test No (n = 152) Yes (n = 47) (Log-Rank Test)
FEV1 .09
≤80% 12 (63%) 7 (37%)
>80% 135 (78%) 38 (22%)
Unknown 5 2
FVC .43
≤80% 16 (70%) 7 (30%)
>80% 130 (77%) 38 (23%)
Unknown 6 2
FEV1/FVC .62
≤80% 7 (87%) 1 (13%)
>80% 139 (76%) 44 (24%)
Unknown 6 2
DLCO .62
≤80% 47 (77%) 14 (23%)
>80% 82 (80%) 21 (20%)
Unknown 23 12
*FEV1 indicates forced expiratory volume in 1 second; FVC, forced
vital capacity; DLCO, carbon monoxide diffusing capacity.
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the efﬁcacy of growth factors appears to depend on whether
MTX is used for GVHD prophylaxis. In patients who
receive MTX, growth factors have not demonstrated earlier
engraftment or other clinical beneﬁts [25-28]. In contrast, for
patients who receive CYA with or without steroids or TCD
alone as GVHD prophylaxis, growth factors have led to
earlier engraftment [18,19,25,26, 29-31]. Whether earlier
engraftment after allogeneic BMT translates into clinical ben-
eﬁts remains controversial. One randomized trial concluded
that earlier engraftment from granulocyte-macrophage CSF
resulted in decreased mucositis, infections, and duration of
hospitalization, whereas another similar randomized trial
concluded that earlier engraftment did not lead to improved
clinical outcomes [29,30]. Interestingly, some case reports
have even implicated G-CSF in the development of pul-
monary complications such as interstitial pneumonitis [32-34].
Our study did not conﬁrm these implications but did show
that TCD transplant recipients who received G-CSF
achieved engraftment earlier than those who received
CYA/MTX without G-CSF support. The significance of
this earlier engraftment and its implications for the lower
incidence of SPCs remains speculative.
The beneﬁts of TCD extend beyond a mere reduction
in the incidence of GVHD. Allogeneic T cell–depleted
BMT has also been associated with a lower incidence of
early posttransplantation toxicities such hepatic veno-occlu-
sive disease and acute renal failure [35-37]. The ﬁndings of
this study further demonstrate that TCD protects against
severe pulmonary events during the early post-BMT period.
Because pulmonary complications are the major cause of
death within the ﬁrst 100 days of BMT, this protective effect
is a likely reason for the improved up-front survival
observed after TCD allogeneic transplantation.
Our ﬁnding of an association between FEV1 and SPCs
is concordant with previous reports demonstrating an asso-
ciation between abnormal pretransplantation pulmonary
function tests and early mortality after BMT [38-40]. Gold-
berg et al. have reported that a pretransplantation FEV1 of
≤78% of that predicted was associated with a greater inci-
dence of day 100 toxic mortality after BMT [39]. Our study
further shows that smoking is not associated with the devel-
opment of SPCs. The association of a reduced pretransplan-
tation FEV1 (≤80% of predicted) with increased risk for
SPCs could have future clinical applications in the screening
of candidates for stem cell transplantation. In particular, for
patients with compromised FEV1 who require allogeneic
stem cell transplantation, extra consideration should be
given to the type of GVHD prophylaxis used. Because TCD
is associated with a lower incidence of early posttransplanta-
tion toxicity and fewer SPCs, it should be strongly consid-
ered for those with impaired pulmonary function.
A better understanding of the pathogenesis of early SPCs
after transplantation will be crucial if we are to make allo-
geneic BMT safer and more widely applicable in the future.
Infectious triggers, inﬂammatory cellular activity, toxic drug
effects, and release of cytokines such as interleukin-1 and -2,
tumor necrosis factor–α, and interferon-γ may all play critical
roles in mediating injury to the lung parenchyma. Informative
animal models are needed to help delineate the pathogenesis
of these complications so that we may understand why TCD
offers a protective effect against SPCs and how we can pre-
vent these devastating complications.
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Figure 1. Kaplan-Meier curves showing time to onset of severe pul-
monary complication (SPC) stratiﬁed by type of graft-versus-host dis-
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